Ras-ling with new therapeutic targets for metastasis

References

• Buchheit CL, Rayavarapu RR, Schafer ZT. The regulation of cancer cell death and metabolism by extracellular matrix attachment. Semin Cell Dev Biol 2012; 23:402-11; PMID:22579674; http://dx.doi.org/10.1016/j.semcdb.2012.04.007
   PubMed Web of Science ®Google Scholar
• Buchheit CL, Weigel KJ, Schafer ZT. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer 2014; 14:632-41; PMID:25098270; http://dx.doi.org/10.1038/nrc3789
   PubMed Web of Science ®Google Scholar
• Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124:619-26; PMID:8106557; http://dx.doi.org/10.1083/jcb.124.4.619
   PubMed Web of Science ®Google Scholar
• Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005; 5:675-88; PMID: 16148884; http://dx.doi.org/10.1038/nrc1695
   PubMed Web of Science ®Google Scholar
• Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 2002; 111:29-40; PMID:12372298; http://dx.doi.org/10.1016/S0092-8674(02)01001-2
   PubMed Web of Science ®Google Scholar
• Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J, Muthuswamy SK, Brugge JS. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003; 5:733-40; PMID:12844146; http://dx.doi.org/10.1038/ncb1026
   PubMed Web of Science ®Google Scholar
• Davison CA, Durbin SM, Thau MR, Zellmer VR, Chapman SE, Diener J, Wathen C, Leevy WM, Schafer ZT. Antioxidant enzymes mediate survival of breast cancer cells deprived of extracellular matrix. Cancer Res 2013; 73:3704-15; PMID:23771908; http://dx.doi.org/10.1158/0008-5472.CAN-12-2482
   PubMed Web of Science ®Google Scholar
• Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P, Brugge JS. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009; 461:109-13; PMID:19693011; http://dx.doi.org/10.1038/nature08268
   PubMed Web of Science ®Google Scholar
• Buchheit CL, Angarola BL, Steiner A, Weigel KJ, Schafer ZT. Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration. Cell Death Differ 2015; 22:1275-86; PMID:25526094; http://dx.doi.org/10.1038/cdd.2014.209; PMID: 25526094; http://dx.doi.org/10.1038/cdd.2014.209
   PubMed Web of Science ®Google Scholar
• Weigel KJ, Jakimenko A, Conti BA, Chapman SE, Kaliney WJ, Leevy WM, Champion MM, Schafer ZT. CAF-secreted IGFBPs regulate breast cancer cell anoikis. Mol Cancer Res 2014; 12:855-66; PMID:24803643; http://dx.doi.org/10.1158/1541-7786.MCR-14-0090
   PubMed Web of Science ®Google Scholar
• Rayavarapu RR, Heiden B, Pagani N, Shaw MM, Shuff S, Zhang S, Schafer ZT. The role of multicellular aggregation in the survival of ErbB2-positive breast cancer cells during extracellular matrix detachment. J Biol Chem 2015; 290:8722-33; PMID:25681438; http://dx.doi.org/10.1074/jbc.M114.612754
   PubMed Web of Science ®Google Scholar
• Mason JA, Davison-Versagli CA, Leliaert AK, Pape DJ, McCallister C, Zuo J, Durbin SM, Buchheit CL, Zhang S, Schafer ZT. Oncogenic Ras differentially regulates metabolism and anoikis in extracellular matrix-detached cells. Cell Death Differ 2016; 23:1271-82; PMID:26915296; http://dx.doi.org/10.1038/cdd.2016.15
   PubMed Web of Science ®Google Scholar
• Mason JA, Schafer ZT. SGK-1 and PHLPP1: Ras-mediated effectors during ECM-detachment. Cell Cycle 2016; 15:2233-4; PMID:27267605; http://dx.doi.org/10.1080/15384101.2016.1194136
   PubMed Web of Science ®Google Scholar
• Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012; 72:2457-67; PMID:22589270; http://dx.doi.org/10.1158/0008-5472.can-11-2612
   PubMed Web of Science ®Google Scholar
• Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11:761-74; PMID:21993244; http://dx.doi.org/10.1038/nrc3106
   PubMed Web of Science ®Google Scholar
• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11-22; PMID:12509763; http://dx.doi.org/10.1038/nrc969
   PubMed Web of Science ®Google Scholar
• Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov 2014; 13:928-42; PMID:25435214; http://dx.doi.org/10.1038/nrd4281
   PubMed Web of Science ®Google Scholar
• Bruhn MA, Pearson RB, Hannan RD, Sheppard KE. Second AKT: the rise of SGK in cancer signalling. Growth Factors 2010; 28:394-408; PMID:20919962; http://dx.doi.org/10.3109/08977194.2010.518616
   PubMed Web of Science ®Google Scholar
• Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 2010; 11:9-22; PMID:20027184; http://dx.doi.org/10.1038/nrm2822
   PubMed Web of Science ®Google Scholar
• Jeyaraj S, Boehmer C, Lang F, Palmada M. Role of SGK1 kinase in regulating glucose transport via glucose transporter GLUT4. Biochem Biophys Res Commun 2007; 356:629-35; PMID:17382906; http://dx.doi.org/10.1016/j.bbrc.2007.03.029
   PubMed Web of Science ®Google Scholar
• Palmada M, Boehmer C, Akel A, Rajamanickam J, Jeyaraj S, Keller K, Lang F. SGK1 kinase upregulates GLUT1 activity and plasma membrane expression. Diabetes 2006; 55:421-7; PMID:16443776; http://dx.doi.org/10.2337/diabetes.55.02.06.db05-0720
   PubMed Web of Science ®Google Scholar
• Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V. (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev 2006; 86:1151-78; PMID:17015487; http://dx.doi.org/10.1152/physrev.00050.2005
   PubMed Web of Science ®Google Scholar
• Amato R, Scumaci D, D'Antona L, Iuliano R, Menniti M, Di Sanzo M, Faniello MC, Colao E, Malatesta P, Zingone A, et al. Sgk1 enhances RANBP1 transcript levels and decreases taxol sensitivity in RKO colon carcinoma cells. Oncogene 2013; 32:4572-8; PMID:23108393; http://dx.doi.org/10.1038/onc.2012.470
   PubMed Web of Science ®Google Scholar
• Talarico C, Dattilo V, D'Antona L, Menniti M, Bianco C, Ortuso F, Alcaro S, Schenone S, Perrotti N, Amato R. SGK1, the New Player in the Game of Resistance: Chemo-Radio Molecular Target and Strategy for Inhibition. Cell Physiol Biochem 2016; 39:1863-76; PMID:27771704; http://dx.doi.org/10.1159/000447885
   PubMed Web of Science ®Google Scholar
• Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, et al. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kalpha Inhibition. Cancer Cell 2016; 30:229-42; PMID:27451907; http://dx.doi.org/10.1016/j.ccell.2016.06.004
   PubMed Web of Science ®Google Scholar
• Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 2015; 163:506-19; PMID:26451490; http://dx.doi.org/10.1016/j.cell.2015.09.033
   PubMed Web of Science ®Google Scholar
• Fagerli UM, Ullrich K, Stuhmer T, Holien T, Kochert K, Holt RU, Bruland O, Chatterjee M, Nogai H, Lenz G, et al. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells. Oncogene 2011; 30:3198-206; PMID:21478911; http://dx.doi.org/10.1038/onc.2011.79
   PubMed Web of Science ®Google Scholar
• Hall BA, Kim TY, Skor MN, Conzen SD. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression. Breast Cancer Res Treat 2012; 135:469-79; PMID:22842983; http://dx.doi.org/10.1007/s10549-012-2161-y
   PubMed Web of Science ®Google Scholar
• Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, Zagaja GP, Brendler CB, Stadler WM, Conzen SD. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate 2012; 72:157-64; PMID:21563193; http://dx.doi.org/10.1002/pros.21416
   PubMed Web of Science ®Google Scholar
• Kach J, Conzen SD, Szmulewitz RZ. Targeting the glucocorticoid receptor in breast and prostate cancers. Sci Transl Med 2015; 7:305ps19; PMID:26378243; http://dx.doi.org/10.1126/scitranslmed.aac7531
   PubMedGoogle Scholar
• Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res 2013; 19:6163-72; PMID:24016618; http://dx.doi.org/10.1158/1078-0432.CCR-12-3826
   PubMed Web of Science ®Google Scholar
• Sommer EM, Dry H, Cross D, Guichard S, Davies BR, Alessi DR. Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. Biochem J 2013; 452:499-508; PMID:23581296; http://dx.doi.org/10.1042/bj20130342
   PubMed Web of Science ®Google Scholar
• D'Antona L, Amato R, Talarico C, Ortuso F, Menniti M, Dattilo V, Iuliano R, Gigliotti F, Artese A, Costa G, et al. SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation. Cell Physiol Biochem 2015; 35:2006-18; PMID:25871776; http://dx.doi.org/10.1159/000374008
   PubMed Web of Science ®Google Scholar
• Talarico C, D'Antona L, Scumaci D, Barone A, Gigliotti F, Fiumara CV, Dattilo V, Gallo E, Visca P, Ortuso F, et al. Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy. Oncotarget 2015; 6:37511-25; PMID:26462020; http://dx.doi.org/10.18632/oncotarget.5527
   PubMed Web of Science ®Google Scholar
• Talarico C, Dattilo V, D'Antona L, Barone A, Amodio N, Belviso S, Musumeci F, Abbruzzese C, Bianco C, Trapasso F, et al. SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells. Oncotarget 2016; 7:15868-84; PMID:26908461; http://dx.doi.org/10.18632/oncotarget.7520
   PubMed Web of Science ®Google Scholar
• Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005; 18:13-24; PMID:15808505; http://dx.doi.org/10.1016/j.molcel.2005.03.008
   PubMed Web of Science ®Google Scholar
• Newton AC, Trotman LC. Turning off AKT: PHLPP as a drug target. Annu Rev Pharmacol Toxicol 2014; 54:537-58; PMID:24392697; http://dx.doi.org/10.1146/annurev-pharmtox-011112-140338
   PubMed Web of Science ®Google Scholar
• Cai J, Fang L, Huang Y, Li R, Yuan J, Yang Y, Zhu X, Chen B, Wu J, Li M. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res 2013; 73:5402-15; PMID:23856247; http://dx.doi.org/10.1158/0008-5472.CAN-13-0297
   PubMed Web of Science ®Google Scholar
• Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O'Neill A, Castillo-Martin M, Nowak DG, Naguib A, Grace DM, et al. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 2011; 20:173-86; PMID:21840483; http://dx.doi.org/10.1016/j.ccr.2011.07.013
   PubMed Web of Science ®Google Scholar
• Wang P, Zhou Z, Hu A, Ponte de Albuquerque C, Zhou Y, Hong L, Sierecki E, Ajiro M, Kruhlak M, Harris C, et al. Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. Mol Cell 2014; 54:378-91; PMID:24703948; http://dx.doi.org/10.1016/j.molcel.2014.03.007
   PubMed Web of Science ®Google Scholar
• Wen YA, Stevens PD, Gasser ML, Andrei R, Gao T. Downregulation of PHLPP expression contributes to hypoxia-induced resistance to chemotherapy in colon cancer cells. Mol Cell Biol 2013; 33:4594-605; PMID:24061475; http://dx.doi.org/10.1128/MCB.00695-13
   PubMed Web of Science ®Google Scholar
• Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009; 16:259-66; PMID:19732725; http://dx.doi.org/10.1016/j.ccr.2009.07.016
   PubMed Web of Science ®Google Scholar
• Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W, Stein J, Stein GS, Iglehart JD, Shi Q, et al. Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell 2010; 38:512-23; PMID:20513427; http://dx.doi.org/10.1016/j.molcel.2010.03.017
   PubMed Web of Science ®Google Scholar
• Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007; 8:341-52; PMID:17440531; http://dx.doi.org/10.1038/nrg2101
   PubMed Web of Science ®Google Scholar